**Background of CDH11 Antibody**
CDH11 (Cadherin-11), a member of the cadherin superfamily, is a calcium-dependent transmembrane glycoprotein involved in cell-cell adhesion, tissue morphogenesis, and cellular signaling. Primarily expressed in mesenchymal cells, such as osteoblasts, fibroblasts, and smooth muscle cells, CDH11 plays critical roles in skeletal development, joint formation, and wound healing. Its extracellular domain contains cadherin repeats that mediate homophilic interactions, while the intracellular domain binds catenins to link the actin cytoskeleton.
CDH11 dysregulation is implicated in pathological conditions, including osteoporosis, rheumatoid arthritis, fibrosis, and cancer metastasis. In oncology, CDH11 overexpression correlates with tumor invasion and poor prognosis in breast, prostate, and thyroid cancers. In inflammatory diseases, it contributes to synovial fibroblast activation and joint destruction.
CDH11 antibodies are essential tools for detecting CDH11 expression in research and diagnostics. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study its localization, expression levels, and functional roles. Therapeutic applications are also emerging, with antibodies targeting CDH11 to inhibit pathological cell adhesion or signaling in autoimmune disorders and cancer.
Overall, CDH11 antibodies provide critical insights into tissue development, disease mechanisms, and potential therapeutic strategies.